Clinical Trial Detail

NCT ID NCT04113616
Title An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Kartos Therapeutics, Inc.
Indications

acute myeloid leukemia

Therapies

Decitabine + KRT-232

Cytarabine + KRT-232

Age Groups: adult senior

Additional content available in CKB BOOST